Kopion Asset Management LLC Cuts Holdings in Certara, Inc. $CERT

Key Points

• Kopion Asset Management cut its Certara stake by 17.6% in the third quarter, selling 326,175 shares and retaining 1.53 million shares valued at about $14.1 million. Certara remains Kopion’s second-largest holding and represents 9.3% of its portfolio.
• Institutional ownership of Certara stands at 73.96%, with BlackRock, Haveli Investment Management, Jefferies and other firms recently establishing new positions.
• Analysts maintain a consensus “Hold” rating with an average price target of $8.60. Certara recently missed quarterly EPS and revenue estimates, while its shares traded at $9.13, up from a 52-week low of $4.45.

Kopion Asset Management LLC reduced its stake in Certara, Inc. (NASDAQ:CERT - Free Report) by 17.6% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,532,364 shares of the company's stock after selling 326,175 shares during the quarter. Certara makes up 9.3% of Kopion Asset Management LLC's investment portfolio, making the stock its 2nd largest holding. Kopion Asset Management LLC owned approximately 1.00% of Certara worth $14,098,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Certara in the second quarter valued at approximately $123,259,000. Haveli Investment Management LLC acquired a new position in Certara in the 2nd quarter valued at $48,470,000. Jefferies Financial Group Inc. acquired a new position in Certara in the 2nd quarter valued at $46,446,000. Bank of America Corp DE bought a new position in Certara in the 2nd quarter worth $11,780,000. Finally, Tejara Capital Ltd bought a new position in Certara in the 2nd quarter worth $8,467,000. Institutional investors and hedge funds own 73.96% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on CERT. Weiss Ratings raised Certara from a "sell (e+)" rating to a "sell (d)" rating in a research report on Wednesday, August 5th. Barclays increased their target price on Certara from $7.50 to $9.00 and gave the company an "equal weight" rating in a research note on Wednesday. Finally, UBS Group reaffirmed a "neutral" rating and issued a $10.00 price target on shares of Certara in a research report on Wednesday, September 30th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Certara currently has a consensus rating of "Hold" and a consensus price target of $8.60.

Certara Stock Performance

Certara stock traded up $0.49 during trading hours on Friday, hitting $9.13. The stock had a trading volume of 2,248,990 shares, compared to its average volume of 3,505,223. The company has a 50-day moving average of $8.38 and a two-hundred day moving average of $6.84. The company has a quick ratio of 2.55, a current ratio of 2.55 and a debt-to-equity ratio of 0.30. Certara, Inc. has a fifty-two week low of $4.45 and a fifty-two week high of $13.11. The company has a market cap of $1.39 billion, a PE ratio of -20.30 and a beta of 1.42.

Certara (NASDAQ:CERT - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by ($0.01). The firm had revenue of $93.27 million for the quarter, compared to the consensus estimate of $98.09 million. Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The business's revenue for the quarter was down 10.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.07 earnings per share. On average, equities research analysts anticipate that Certara, Inc. will post 0.22 EPS for the current fiscal year.

Certara Company Profile

Certara, Inc NASDAQ: CERT provides software and technology-enabled services for the biopharmaceutical industry. The company helps drug developers use regulatory science, data analysis, and modeling and simulation to support decisions throughout the research, development, and commercialization lifecycle.

Its offerings include software for pharmacokinetic and pharmacodynamic modeling, clinical trial design, patient and disease modeling, regulatory submissions, and real-world data analysis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.